Aldevron

History

2021: Danaher bought Aldevron for $9.6 billion

In June 2021, Danaher announced the acquisition of Aldevron, a manufacturer of biological components for vaccines, for $9.6 billion.

Aldevron of Fargo, North Dakota, which has about 600 people, produces high-quality plasmid DNA, mRNA, and protein drugs for biotechnology and pharmaceutical clients for research, clinical, and commercial applications.

Danaher bought Aldevron, a manufacturer of biological components for vaccines

According to the press release, after the acquisition, Aldevron will continue to operate as a separate company within Danaher and will retain its brand in the business segment of the corporation. Danaher expects to finance the acquisition of $9.6 billion from cash and/or proceeds from the issuance of commercial securities. The transaction will be finalized under normal conditions, including obtaining appropriate regulatory approvals.

We are very pleased that Aldevron has joined Danaher's biomedical sciences segment. For almost 25 years, Aldevron has made a huge contribution to the development of cellular, gene and other newest methods of treating and creating vaccines, "said Rainer M. Blair, President and Chief Executive Officer of Danaher, in a press release. - This acquisition will expand our genomic medicine capabilities and help support our customers and their important projects to bring vital treatments and new vaccines to market faster.

In turn the founder and the executive chairman of Aldevron Michael Chambers noted that accession to Danaher will help the company to expand coverage of the international market and to use possibilities of larger Danaher business system for involvement of new clients.^[1]

Notes